Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

Company Overview

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines. Bruce Cozadd, a company co-founder, serves as chairman and chief executive officer.

Key Stats

• Today's Range: $235.89 to $243.25
• 50-Day Range: $205.06 to $248.24
• 52-Week Range: $139.26 to $266.38
• Volume: 496,700 shs
• Average Volume: 813,001 shs
• Market Capitalization: $15.51 billion
• P/E Ratio: 82.16
• Dividend Yield: N/A
• Price Target: $294.25
• Consensus Rating: Moderate Buy

Jazz Pharmaceuticals Stock Analysis - MarketRank™

Jazz Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 15th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 1 strong buy rating, 17 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Jazz Pharmaceuticals has a consensus price target of $294.25, representing about 21.8% upside from its current price of $241.55.

Amount of Analyst Coverage

Jazz Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 112.09%

Earnings Growth

Earnings for Jazz Pharmaceuticals are expected to grow by 112.09% in the coming year, from $11.08 to $23.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jazz Pharmaceuticals is 82.16, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jazz Pharmaceuticals is 82.16, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.

Price to Earnings Growth Ratio

Jazz Pharmaceuticals has a PEG Ratio of 0.44. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Jazz Pharmaceuticals has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.42% of the float of Jazz Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.67.

Change versus previous month

Short interest in Jazz Pharmaceuticals has recently decreased by 1.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jazz Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Jazz Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.87

News Sentiment

Jazz Pharmaceuticals has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Jazz Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

23 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.

MarketBeat Follows

3 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,420,491.00 in company stock.

Percentage Held by Insiders

4.10% of the stock of Jazz Pharmaceuticals is held by insiders.

Percentage Held by Institutions

89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/02/2026
• Today: 11/14/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• 38th Annual Healthcare Conference: 12/02/2026
• Citi Annual Global Healthcare Conference 2026: 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:JAZZ
• CIK: 1232524
• Web: www.jazzpharma.com
• Phone: (531) 634-7800
• Fax: 353-1634-7850
• Employees: 2,890
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Jazz Pharmaceuticals: $294.25
• High Price Target: $337.00
• Low Price Target: $220.00
• Potential Upside/Downside: +21.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.95
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.94
• Trailing P/E Ratio: 82.16
• Forward P/E Ratio: 10.28
• P/E Growth: 0.44
• Net Income: -$356.15 million
• Net Margins: 4.37%
• Pretax Margin: 5.51%
• Return on Equity: 16.88%
• Return on Assets: 6.46%

Debt

• Debt-to-Equity Ratio: 1.09
• Current Ratio: 1.82
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: $4.27 billion
• Price / Sales: 3.63
• Cash Flow: $16.34 per share
• Price / Cash Flow: 14.78
• Book Value: $65.30 per share
• Price / Book: 3.70

Miscellaneous

• Outstanding Shares: 64,190,000
• Free Float: 61,557,000
• Market Cap: $15.51 billion
• Optionable: Optionable
• Beta: 0.38